|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Collaboration revenue | |||||
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Restructuring and impairment charges | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Interest income | |||||
| Other expenses | |||||
| Net loss | |||||
| Net loss per common share, basic (in dollars per share) | |||||
| Net loss per common share, diluted (in dollars per share) | |||||
| Weighted-average shares used to compute net loss per common share, basic (in shares) | |||||
| Weighted-average shares used to compute net loss per common share, diluted (in shares) | |||||
Loading...
